Fate Net Interest Income vs Ebitda Analysis
FATE Stock | USD 4.22 0.07 1.69% |
Fate Therapeutics financial indicator trend analysis is much more than just examining Fate Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fate Therapeutics is a good investment. Please check the relationship between Fate Therapeutics Net Interest Income and its Ebitda accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.
Net Interest Income vs Ebitda
Net Interest Income vs Ebitda Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fate Therapeutics Net Interest Income account and Ebitda. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Fate Therapeutics' Net Interest Income and Ebitda is -0.61. Overlapping area represents the amount of variation of Net Interest Income that can explain the historical movement of Ebitda in the same time period over historical financial statements of Fate Therapeutics, assuming nothing else is changed. The correlation between historical values of Fate Therapeutics' Net Interest Income and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Interest Income of Fate Therapeutics are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Net Interest Income i.e., Fate Therapeutics' Net Interest Income and Ebitda go up and down completely randomly.
Correlation Coefficient | -0.61 |
Relationship Direction | Negative |
Relationship Strength | Weak |
Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Ebitda
Most indicators from Fate Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fate Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.The current year's Selling General Administrative is expected to grow to about 85.5 M, whereas Issuance Of Capital Stock is projected to grow to (26.5 K).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 4.5M | 5.8M | 6.7M | 7.1M | Depreciation And Amortization | 1.3M | 13.8M | 18.3M | 19.2M |
Fate Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Fate Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fate Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 302.3M | 622.5M | 921.5M | 705.6M | 506.2M | 310.1M | |
Short Long Term Debt Total | 26.9M | 97.3M | 114.8M | 109.3M | 103.5M | 108.7M | |
Other Current Liab | 17.5M | 54.8M | 45.6M | 57.9M | 27.5M | 18.9M | |
Total Current Liabilities | 27.8M | 85.6M | 81.3M | 114.1M | 39.1M | 36.6M | |
Total Stockholder Equity | 244.8M | 384.4M | 678.8M | 483.9M | 368.4M | 210.3M | |
Other Liab | 4.5M | 58.5M | 52.1M | 3.9M | 4.4M | 4.2M | |
Property Plant And Equipment Net | 22.8M | 67.1M | 70.7M | 66.1M | 158.5M | 166.4M | |
Current Deferred Revenue | 2.8M | 21.1M | 21.5M | 42.2M | 685K | 650.8K | |
Net Debt | (72.9M) | (70.0M) | (18.8M) | 48.0M | 61.7M | 64.7M | |
Retained Earnings | (383.5M) | (556.9M) | (769.1M) | (1.1B) | (1.2B) | (1.2B) | |
Accounts Payable | 5.8M | 6.3M | 8.6M | 8.3M | 4.7M | 4.0M | |
Cash | 99.8M | 167.3M | 133.6M | 61.3M | 41.9M | 39.8M | |
Non Current Assets Total | 75.2M | 128.1M | 288.0M | 203.5M | 174.7M | 183.4M | |
Non Currrent Assets Other | 13.0M | 32.3M | 116.7M | 132.5M | 9.0K | 8.5K | |
Other Assets | 1.6M | 95.8M | 25.1M | 22.5M | 1.0 | 0.95 | |
Cash And Short Term Investments | 221.4M | 482.9M | 615.9M | 436.2M | 315.2M | 224.2M | |
Common Stock Total Equity | 65K | 76K | 88K | 96K | 110.4K | 115.9K | |
Common Stock Shares Outstanding | 68.2M | 82.4M | 94.7M | 96.8M | 98.4M | 54.2M | |
Liabilities And Stockholders Equity | 302.3M | 622.5M | 921.5M | 705.6M | 506.2M | 310.1M | |
Non Current Liabilities Total | 29.7M | 152.4M | 161.3M | 107.6M | 98.7M | 63.3M | |
Other Current Assets | 4.3M | 5.9M | 8.8M | 27.4M | 13.6M | 14.3M | |
Other Stockholder Equity | 628.2M | 941.2M | 1.4B | 1.5B | 1.6B | 1.7B | |
Total Liab | 57.5M | 238.0M | 242.6M | 221.6M | 137.8M | 99.9M | |
Property Plant And Equipment Gross | 34.2M | 99.4M | 70.7M | 66.1M | 206.1M | 216.4M | |
Total Current Assets | 227.1M | 494.3M | 633.4M | 502.1M | 331.5M | 234.9M | |
Accumulated Other Comprehensive Income | 22K | 70K | (762K) | (1.9M) | 15K | 15.8K | |
Short Term Debt | 1.7M | 3.4M | 5.6M | 5.6M | 6.2M | 4.6M | |
Common Stock | 76K | 88K | 96K | 97K | 99K | 58.1K | |
Property Plant Equipment | 11.4M | 32.3M | 162.2M | 176.1M | 202.5M | 212.6M | |
Net Tangible Assets | 274.5M | 536.9M | 678.8M | 483.9M | 556.5M | 584.4M | |
Retained Earnings Total Equity | (285.4M) | (383.5M) | (556.9M) | (769.1M) | (692.2M) | (657.6M) | |
Short Term Investments | 121.6M | 315.6M | 482.3M | 374.9M | 273.3M | 159.4M | |
Capital Surpluse | 445.8M | 628.2M | 941.2M | 1.4B | 1.7B | 1.7B | |
Deferred Long Term Liab | 1.3M | 13.5M | 9.9M | 7.2M | 8.3M | 5.0M | |
Non Current Liabilities Other | 175K | 549K | 702K | 800K | 920K | 721.9K | |
Net Invested Capital | 244.8M | 384.4M | 678.8M | 483.9M | 368.4M | 381.5M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
CEOs Directory Screen CEOs from public companies around the world | |
Stocks Directory Find actively traded stocks across global markets | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Fate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.92) | Revenue Per Share 0.065 | Quarterly Revenue Growth (0.97) | Return On Assets (0.21) | Return On Equity (0.42) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.